The Next Era of Alzheimer's Treatment: Prevention Trials, Combination Therapies, and Biomarker-Driven Early Detection Converge
核心洞察
Rudolph Tanzi and Reisa Sperling are leading a shift toward Alzheimer's prevention, with the fully enrolled AHEAD 3-45 trial testing lecanemab in cognitively normal individuals with elevated amyloid (搜索), results expected in the late 2020s.
A 2026 Annals of Neurology review supports combination disease-modifying therapy using repurposed drugs including GLP-1 receptor agonists, iron chelators, and chemical chaperones across multiple neurodegenerative targets.
More than 150 therapies are now in nearly 200 clinical trials targeting at least 17 different biological processes, with blood-based biomarkers like plasma pTau217 enabling earlier patient identification and trial enrichment.
The Alzheimer's disease (搜索) field is undergoing a fundamental transformation, moving beyond incremental symptomatic slowing toward a future built on prevention, combination therapy, and biomarker-driven early detection. The scientific community, armed with validated mechanisms and approved drugs, is now directing its attention toward presymptomatic intervention and multi-target treatment regimens that could reshape the therapeutic landscape over the next decade.
Rudolph Tanzi, professor of neurology at Harvard Medical School and co-director of the McCance Center for Brain Health at Massachusetts General Hospital, has been direct about where the field must go. "We're seeing a push now toward trials that are looking at prevention," Tanzi said in 2025. "Alzheimer's disease (搜索) pathology begins in the brain decades before symptoms appear." His argument — that stopping amyloid (搜索) accumulation in the presymptomatic phase requires affordable, safe, and accessible therapies, not just the current generation of expensive infusions — defines one of the field's central tensions. The drugs that exist work best in patients who have already lost ground. Prevention demands reaching people who feel fine.
The Prevention Imperative Takes Shape
Reisa Sperling at Harvard's Brigham and Women's Hospital has translated that imperative into operational trials. Her AHEAD 3-45 trial, now fully enrolled, tests lecanemab in clinically normal individuals with elevated amyloid (搜索) — the first major prevention trial using an approved anti-amyloid therapy in a truly preclinical population. The trial's results, expected in the late 2020s, will determine whether the prevention window can be pharmacologically addressed. If it can, the addressable patient population for anti-amyloid therapy expands by orders of magnitude.
This shift toward earlier detection is already reshaping care. Blood-based biomarkers — including plasma pTau217, neurofilament light chain, and GFAP — are advancing through clinical validation, allowing researchers to enrich trial populations for biologically defined disease rather than clinical symptoms alone. These tools also enable interim monitoring and potentially shorter trials in populations that would otherwise require years of follow-up.
Real-world data generated by the Alzheimer's Association's ALZ-NET is reinforcing the value of early intervention. Even at six months on the new disease-modifying therapies, significant benefits on daily activities — writing checks, paying bills, shopping, tracking current events, engaging with family — are being observed. "This gives more credibility to treatment beyond results on cognitive tests," according to clinicians involved with the registry.
Combination Therapy: The Coming Standard
The field increasingly converges on the view that Alzheimer's and Parkinson's are not single-mechanism diseases and will not yield to single-mechanism treatments. A 2026 review published in Annals of Neurology examined the evidence for combination disease-modifying therapy using repurposed drugs — including GLP-1 receptor agonists, iron chelators, and chemical chaperones — across multiple neurodegenerative targets. The argument is that addressing the overlapping pathologies of amyloid (搜索), tau (搜索), neuroinflammation, and vascular dysfunction simultaneously may produce additive benefit that no single agent achieves.
Industry consensus is moving in the same direction. The treatment paradigm the field anticipates is one where Leqembi or Kisunla — or the next-generation trontinemab — serves as a backbone therapy, and additional agents targeting tau (搜索), neuroinflammation, or synaptic health are layered on top. Novel drugs "must demonstrate additive efficacy alongside Leqembi and Kisunla" to achieve meaningful market access.
Today, more than 150 therapies are being tested across nearly 200 clinical trials, targeting at least 17 different aspects of the disease, including tau (搜索), inflammation, metabolism, and vascular health. The latest pipeline analysis, "Alzheimer's disease (搜索) drug development pipeline: 2026," published in Alzheimer's & Dementia: Translational Research & Clinical Interventions, underscores how quickly the field is evolving beyond any single target.
Genetics and Precision Targeting Advance
The genetic architecture of Alzheimer's disease (搜索) is better understood than at any prior point. APOE4 (搜索) — the strongest common genetic risk factor — is now a recognized therapeutic target, not just a risk stratification tool. Sanofi's acquisition of Vigil Neuroscience and its TREM2 (搜索) agonist VG-3927 reflects the field's growing interest in microglial biology and neuroinflammation. TREM2, expressed on microglia, influences their capacity to clear amyloid (搜索) and manage neuroinflammation, representing a path around the amyloid cascade hypothesis entirely.
For Parkinson's, genetic targeting is advancing through gene therapy. Prevail Therapeutics — acquired by Eli Lilly — has programs targeting GBA1 (搜索), the most common genetic risk factor for Parkinson's, through adeno-associated virus (AAV) delivery. The PARAISO Phase 3 trial, launched in 2025 by Roche and Prothena, tests prasinezumab, an alpha-synuclein (搜索)-targeting antibody, in early Parkinson's. Primary completion is expected in 2029.
The Trial Design Reckoning
As therapies improve and the industry moves toward earlier-stage populations, clinical trial design becomes harder. Cognitive endpoints measured over 18 months show minimal movement in presymptomatic individuals. The 2025 Alzheimer's pipeline analysis by Cummings et al. documented that more than 50,000 patients are needed to populate currently active clinical trials — and that increasing site density and operational efficiency may be as important as any biological innovation.
Blood-based biomarkers are the methodological answer, now standard in every major late-stage program. They allow researchers to enrich trial populations for biologically defined disease and enable interim monitoring.
Lifestyle and Pharmacologic Synergy
The U.S. POINTER trial found that two lifestyle interventions targeting physical activity, nutrition, cognitive and social challenge, and health monitoring improved cognition in older adults at risk of cognitive decline. The cognitive benefits were greater for participants in the more structured intervention group over the nearly two-year study period. The possibilities of combining lifestyle intervention with drug treatment are being explored as a complementary strategy.
What the Next Decade Could Yield
The trajectory points toward several converging outcomes. Prevention trials will generate their first efficacy data in the late 2020s, defining whether anti-amyloid (搜索) therapy can delay or prevent disease onset in at-risk populations. Tau (搜索)-targeting therapies, following the diranersen CELIA results, are likely to enter pivotal development within the next two years. Blood-based diagnostics will drive a step-change in patient identification, expanding the diagnosed population and enabling treatment earlier in the disease course. AI-assisted drug discovery will accelerate preclinical target validation, with companies like Novartis already generating millions of computationally designed candidates against neurodegeneration targets.
What distinguishes this moment from earlier cycles of enthusiasm is the accumulation of validated mechanisms, approved drugs, and investable infrastructure. The combination of Tanzi's genetic insights, Sperling's prevention trials, Biogen's tau (搜索) data, Roche's delivery engineering, and AbbVie (搜索)'s Parkinson's pipeline represents a field attacking brain disease from multiple angles simultaneously — with the tools, capital, and clinical evidence to sustain the effort.
As one clinician-researcher noted, "In complex diseases, the first breakthroughs are not the end of the work. They are the beginning. We have seen this in cancer and MS, where early treatments opened the door to a broader range of therapies that address the disease in different and complementary ways. Alzheimer's is now at that turning point."